Search

Few studies have quantified the multimorbidity burden in older adults with chronic obstructive pulmonary disease (COPD) using large and generalizable data. Such evidence is essential to inform evidence-based research, clinical care, and resource allocation. This retrospective cohort study used a nationally representative sample of Medicare beneficiaries aged 65 years or older with COPD and 1:1 matched (on age, sex, and race) non-COPD beneficiaries to: (1) quantify the prevalence of multimorbidity at COPD onset and one-year later; (2) quantify the rates [per 100 person-years (PY)] of newly diagnosed multimorbidity during in the year prior to and in the year following COPD onset; and (3) compare multimorbidity prevalence in beneficiaries with and without COPD. Among 739,118 eligible beneficiaries with and without COPD, the average number of multimorbidity was 10.0 (SD = 4.7) and 1.0 (SD = 3.3), respectively. The most prevalent multimorbidity at COPD onset and at one-year after, respectively, were hypertension (70.8% and 80.2%), hyperlipidemia (52.2% and 64.8%), anemia (42.1% and 52.0%), arthritis (39.8% and 47.7%), and congestive heart failure (CHF) (31.3% and 38.8%). Conditions with the highest newly diagnosed rates before and following COPD onset, respectively, included hypertension (39.8 and 32.3 per 100 PY), hyperlipidemia (22.8 and 27.6), anemia (17.8 and 20.3), CHF (16.2 and 13.2), and arthritis (12.9 and 13.2). COPD was significantly associated with increased odds of all measured conditions relative to non-COPD controls. This study updates existing literature with more current, generalizable findings of the substantial multimorbidity burden in medically complex older adults with COPD-necessary to inform patient-centered, multidimensional care.Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.1968815 .

Objective In preference-sensitive conditions such as back pain, there can be high levels of variability in the trajectory of patient care. We sought to develop a methodology that extracts a realistic and comprehensive understanding of the patient journey using medical and pharmaceutical insurance claims data. Materials and Methods We processed a sample of 10 000 patient episodes (comprised of 113 215 back pain–related claims) into strings of characters, where each letter corresponds to a distinct encounter with the healthcare system. We customized the Levenshtein edit distance algorithm to evaluate the level of similarity between each pair of episodes based on both their content (types of events) and ordering (sequence of events). We then used clustering to extract the main variations of the patient journey. Results The algorithm resulted in 12 comprehensive and clinically distinct patterns (clusters) of patient journeys that represent the main ways patients are diagnosed and treated for back pain. We further characterized demographic and utilization metrics for each cluster and observed clear differentiation between the clusters in terms of both clinical content and patient characteristics. Discussion Despite being a complex and often noisy data source, administrative claims provide a unique longitudinal overview of patient care across multiple service providers and locations. This methodology leverages claims to capture a data-driven understanding of how patients traverse the healthcare system. Conclusions When tailored to various conditions and patient settings, this methodology can provide accurate overviews of patient journeys and facilitate a shift toward high-quality practice patterns.

Author(s): Ren, Ai; Golden, Bruce; Alt, Frank; Wasil, Edward; Bjarnadottir, Margret; Hirshon, Jon Mark; Pimentel, Laura | Abstract: Introduction: On January 1, 2014, the State of Maryland implemented the Global Budget Revenue (GBR) program. We investigate the impact of GBR on length of stay (LOS) for inpatients in emergency departments (ED) in Maryland.Methods: We used the Hospital Compare data reports from the Centers for Medicare and Medicaid Services (CMS) and CMS Cost Reports Hospital Form 2552-10 from January 1, 2012–March 31, 2016, with GBR hospitals from Maryland and hospitals from West Virginia (WV), Delaware (DE), and Rhode Island (RI). We implemented difference-in-differences analysis and investigated the impact of GBR implementation on the LOS or ED1b scores of Maryland hospitals using a mixed-effects model with a state-level fixed effect, a hospital-level random effect, and state-level heterogeneity.Results: The GBR impact estimator was 9.47 (95% confidence interval [CI], 7.06 to 11.87, p-valuel0.001) for Maryland GBR hospitals, which implies, on average, that GBR implementation added 9.47 minutes per year to the time that hospital inpatients spent in the ED in the first two years after GBR implementation. The effect of the total number of hospital beds was 0.21 (95% CI, 0.089 to 0.330, p-value = 0 .001), which suggests that the bigger the hospital, the longer the ED1b score. The state-level fixed effects for WV were -106.96 (95% CI, -175.06 to -38.86, p-value = 0.002), for DE it was 6.51 (95% CI, -8.80 to 21.82, p-value=0.405), and for RI it was -54.48 (95% CI, -82.85 to -26.10, p-valuel0.001).Conclusion: Our results indicate that GBR implementation has had a statistically significant negative impact on the efficiency measure ED1b of Maryland hospital EDs from January 2014 to April 2016. We also found that the significant state-level fixed effect implies that the same inpatient might experience different ED processing times in each of the four states that we studied. [West J Emerg Med.

This case uses player evaluation and personnel decision making in Major League Baseball (MLB) to introduce many of the key steps of data analytics projects. The data analytics process is a unique c...

We present a theory of how a rational, profit-maximizing firm would respond to pressure for gender pay equity by strategically distributing raises to reduce the pay gap between its female and male employees at minimum cost. Using formal analysis and pay data from a real employer, we show that (1) employees in low-paying jobs and whose pay-related observables are similar to those of men at the firm are most likely to get raises; (2) counterintuitively, some men may get raises, and giving raises to certain women would increase the pay gap; and (3) a firm can reduce the gender pay gap as measured by a much larger percentage than the overall increase in pay to women at the firm. We also identify the conditions under which a firm could “explain away” a gender pay gap using other pay-related observables, such as job category, as well as the conditions under which this strategy would backfire. Our paper helps explain some empirical puzzles, such as the tendency for some men to get raises after gender equity pay reviews, and yields a rich set of implications for empirical research and practice. The online appendix is available at https://doi.org/10.1287/orsc.2018.1248 .

Having accurate, unbiased prognosis information can help patients and providers make better decisions about what course of treatment to take. Using a comprehensive dataset of all colorectal cancer patients in California, we generate predictive models that estimate short‐term and medium‐term survival probabilities for patients based on their clinical and demographic information. Our study addresses some of the contradictions in the literature about survival rates and significantly improves predictive power over the performance of any model in previously published studies.

Background Heart failure (HF) is associated with high mortality rates and high costs, and self-care is crucial in the management of the condition. Telehealth can promote patients’ self-care while providing frequent feedback to their health care providers about the patient’s compliance and symptoms. A number of technologies have been considered in the literature to facilitate telehealth in patients with HF. An important factor in the adoption of these technologies is their ease of use. Conversational agent technologies using a voice interface can be a good option because they use speech recognition to communicate with patients. Objective The aim of this paper is to study the engagement of patients with HF with voice interface technology. In particular, we investigate which patient characteristics are linked to increased technology use. Methods We used data from two separate HF patient groups that used different telehealth technologies over a 90-day period. Each group used a different type of voice interface; however, the scripts followed by the two technologies were identical. One technology was based on Amazon’s Alexa (Alexa+), and in the other technology, patients used a tablet to interact with a visually animated and voice-enabled avatar (Avatar). Patient engagement was measured as the number of days on which the patients used the technology during the study period. We used multiple linear regression to model engagement with the technology based on patients’ demographic and clinical characteristics and past technology use. Results In both populations, the patients were predominantly male and Black, had an average age of 55 years, and had HF for an average of 7 years. The only patient characteristic that was statistically different (P=.008) between the two populations was the number of medications they took to manage HF, with a mean of 8.7 (SD 4.0) for Alexa+ and 5.8 (SD 3.4) for Avatar patients. The regression model on the combined population shows that older patients used the technology more frequently (an additional 1.19 days of use for each additional year of age; P=.004). The number of medications to manage HF was negatively associated with use (−5.49; P=.005), and Black patients used the technology less frequently than other patients with similar characteristics (−15.96; P=.08). Conclusions Older patients’ higher engagement with telehealth is consistent with findings from previous studies, confirming the acceptability of technology in this subset of patients with HF. However, we also found that a higher number of HF medications, which may be correlated with a higher disease burden, is negatively associated with telehealth use. Finally, the lower engagement of Black patients highlights the need for further study to identify the reasons behind this lower engagement, including the possible role of social determinants of health, and potentially create technologies that are better tailored for this population.

Postmarketing drug surveillance is the process of monitoring the adverse events of pharmaceutical or medical devices after they are approved by the appropriate regulatory authorities. Historically, such surveillance was based on voluntary reports by medical practitioners, but with the widespread adoption of electronic medical records and comprehensive patient databases, surveillance systems that utilize such data are of considerable interest. Unfortunately, existing methods for analyzing the data in such systems ignore the open-ended exploratory nature of such systems that requires the assessment of multiple possible adverse events. In this article, we propose a method, SEQMEDS, that assesses the effect of a single drug on multiple adverse events by analyzing data that accumulate sequentially and explicitly captures interdependencies among the multiple events. The method continuously monitors a vector-valued test-statistic derived from the cumulative number of adverse events. It flags a potential adverse event once the test-statistic crosses a stopping boundary. We employ asymptotic analysis that assumes a large number of observations in a given window of time to show how to compute the stopping boundary by solving a convex optimization problem that achieves a desired Type I error and minimizes the expected time to detection under a pre-specified alternative hypothesis. We apply our method to a model in which the interdependency among the multiple adverse events is captured by a Cox proportional hazards model with time-dependent covariates and demonstrate that it provides an approximation of a fully sequential test for the maximum hazard ratio of the drug over multiple adverse events. A numerical study verifies that our method delivers Type I /II errors that are below pre-specified levels and is robust to distributional assumptions and parameter values.

Large exposure rules are considered critical for financial institutions, as they directly restrict the lending activity of banks to clients. However, empirical evidence suggests that those rules are difficult both for regulators to enforce and for financial institutions to implement. We present a data-driven analytical model that automatically and algorithmically creates groups of related parties based on ownership information, financial dependencies, business associations, and family ties. We develop a methodology based on linear algebra and networks to group clients, highlight missing critical information, and identify unreported business partners. The approach can be used both prospectively by banking institutions analyzing credit risk and by regulators. We include a case study, applying the methodology retrospectively to highlight large exposure violations and systemic risk leading up to the 2008 banking crises in Iceland.

INTRODUCTION The use of opioids has increased drastically over the past few years and decades. As a result, concerns have mounted over serious outcomes associated with chronic opioid use (COU), including dependency and death. A greater understanding of the factors that are associated with COU will be critical if prescribers are to navigate potentially competing objectives to provide compassionate care, while reducing the overall opioid use problem. In this study, we study pain levels and opioid prescription volumes and their effects on the risk of COU.This study leveraged passive data sources that support automated decision support systems (DSSs) currently employed in a large military population. The models presented compute monthly, person-specific, adjusted probability of subsequent COT and could potentially provide critical decision support for clinicians engaged in pain management. MATERIALS AND METHODS The study population included all outpatient presentations at military medical facilities worldwide among active duty United States Army soldiers during July 2011 to September 2014 (17,664,006 encounters; population N = 552,193). We conducted a retrospective cohort study of this population and employed longitudinal data and a discrete time multivariable logistic regression model to compute COT probability scores. The contribution of pain scores and opioid prescription quantities to the probability of COT represented analytic foci. RESULTS There were 13,891 subjects (2.5%) who experienced incident COT during the observed time period. Statistically significant interactions between pain scores and prescription quantity were present, in addition to effects of multiple other control variables. Counts of monthly opioid prescriptions and maximum stated pain scores per month were each positively associated with COT. A wide range in individual COT risk scores was evident. The effect of prescription volume on the COT risk was larger than the effect of the pain score, and the combined effect of larger pain scores and increased prescription quantity was moderated by the interaction term. CONCLUSIONS The results verified that passive data on the US Army can support a robust COT risk computation in this population. The individual, adjusted risk level requires statistical analyses to be fully understood. Because the same data sources drive current military DSSs, this work provides the potential basis for new, evidence-based decision support resources for military clinicians. The strong, independent impact of increasing opioid prescription counts on the COT risk reinforces the importance of exploring alternatives to opioids in pain management planning. It suggests that changing provider behavior through enhanced decision support could help reduce COT rates.

The rising cost of health care is one of the world's most important problems. Accordingly, predicting such costs with accuracy is a significant first step in addressing this problem. Since the 1980s, there has been research on the predictive modeling of medical costs based on (health insurance) claims data using heuristic rules and regression methods. These methods, however, have not been appropriately validated using populations that the methods have not seen. We utilize modern data-mining methods, specifically classification trees and clustering algorithms, along with claims data from over 800,000 insured individuals over three years, to provide rigorously validated predictions of health-care costs in the third year, based on medical and cost data from the first two years. We quantify the accuracy of our predictions using unseen (out-of-sample) data from over 200,000 members. The key findings are: (a) our data-mining methods provide accurate predictions of medical costs and represent a powerful tool for prediction of health-care costs, (b) the pattern of past cost data is a strong predictor of future costs, and (c) medical information only contributes to accurate prediction of medical costs of high-cost members.